Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Talmadge E. King, Williamson Z. Bradford, Socorro Castro-Bernardini et al. · New England Journal of Medicine · 2014 · 3.8K citations · Full text

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

Paul W. Noble, Carlo Albera, Williamson Z. Bradford et al. · The Lancet · 2011 · 2.1K citations

Antifibrotic Therapy, Idiopathic Pulmonary Fibrosis, Pharmacology +6

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline

Ganesh Raghu, Bram Rochwerg, Yuan Zhang et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 1.9K citations

TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT)

Hidenori Kasai, Jeremy Allen, Roger M. Mason et al. · Respiratory Research · 2005 · 732 citations · Full text

Idiopathic Pulmonary Fibrosis

Moisés Selman, Mayra Mejía, Annie Pardo · 2007 · 499 citations

Antifibrotic Therapy, Fibrosis, Pulmonary Pathology +7